Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells

被引:9
作者
Jia, Yaxun [1 ]
Wang, Min [1 ]
Sang, Xiaolin [1 ]
Liu, Pixu [2 ]
Gao, Jingchun [3 ]
Jiang, Kui [4 ]
Cheng, Hailing [1 ]
机构
[1] Dalian Med Univ, Hosp 2, Dalian Key Lab Mol Targeted Canc Therapy, Canc Inst, Dalian, Peoples R China
[2] Dalian Med Univ, Inst Canc Stem Cell, Dalian, Peoples R China
[3] Dalian Med Univ, Hosp 1, Dept Obstet & Gynecol, Dalian, Peoples R China
[4] Dalian Med Univ, Hosp 2, Dept Med Oncol, Dalian, Peoples R China
来源
FRONTIERS IN ONCOLOGY | 2022年 / 11卷
基金
中国国家自然科学基金;
关键词
BMN; 673; high-grade serous ovarian cancer; PARP inhibitor; phenethyl isothiocyanate; reactive oxygen species; OXIDATIVE STRESS; ORGANIC ISOTHIOCYANATES; THERAPY; RESISTANCE; COMBINATION; ONCOGENE; OLAPARIB;
D O I
10.3389/fonc.2021.812264
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
While PARP inhibitor (PARPi) therapies have shown promising results in the treatment of high-grade serous ovarian cancer (HGSOC) harboring homologous recombination deficiencies, primary resistance to PARPi frequently occurs and even initial responders may eventually become resistant. Therefore, the development of novel effective combinatorial strategies to treat HGSOC is urgently needed. Here, we report that H2O2-induced oxidative stress sensitized HGSOC cells to PARPi BMN 673. Furthermore, Phenethyl isothiocyanate (PEITC) as a ROS-inducing agent significantly enhanced the cytotoxic effects of BMN 673. Mechanistically, combined use of PEITC and BMN 673 resulted in ROS overproduction and accumulation, enhanced DNA damage, G2/M arrest and apoptosis, all of which were significantly reversed by the ROS scavenger N-Acetyl-L-cysteine. We also showed that while PEITC did not further enhance the ability of BMN 673 on PARP1 trapping in HGSOC cells, the therapeutic effects of the PEITC/BMN 673 combination were at least in part dependent on the presence of PARP1. Importantly, the PEITC/BMN 673 combination potently abrogated the growth of HGSOC tumor spheroids and patient-derived organoid models of HGSOC and cervical cancer. Our findings provide a basis for further investigation of the utility of PARPi combination regimen in HGSOC and cervical cancer through ROS-mediated mechanisms.
引用
收藏
页数:13
相关论文
共 52 条
[1]   Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth [J].
Aggarwal, M. ;
Saxena, R. ;
Sinclair, E. ;
Fu, Y. ;
Jacobs, A. ;
Dyba, M. ;
Wang, X. ;
Cruz, I. ;
Berry, D. ;
Kallakury, B. ;
Mueller, S. C. ;
Agostino, S. D. ;
Blandino, G. ;
Avantaggiati, M. L. ;
Chung, F-L .
CELL DEATH AND DIFFERENTIATION, 2016, 23 (10) :1615-1627
[2]   p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition [J].
Aggarwal, Monika ;
Saxena, Rahul ;
Asif, Nasir ;
Sinclair, Elizabeth ;
Tan, Judy ;
Cruz, Idalia ;
Berry, Deborah ;
Kallakury, Bhaskar ;
Quynhchi Pham ;
Wang, Thomas T. Y. ;
Chung, Fung-Lung .
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2019, 38 (1)
[3]   Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method-Letter [J].
Ashton, John C. .
CANCER RESEARCH, 2015, 75 (11) :2400-2400
[4]   Synthetic lethal therapies for cancer: what's next after PARP inhibitors? [J].
Ashworth, Alan ;
Lord, Christopher J. .
NATURE REVIEWS CLINICAL ONCOLOGY, 2018, 15 (09) :564-576
[5]   Integrated genomic analyses of ovarian carcinoma [J].
Bell, D. ;
Berchuck, A. ;
Birrer, M. ;
Chien, J. ;
Cramer, D. W. ;
Dao, F. ;
Dhir, R. ;
DiSaia, P. ;
Gabra, H. ;
Glenn, P. ;
Godwin, A. K. ;
Gross, J. ;
Hartmann, L. ;
Huang, M. ;
Huntsman, D. G. ;
Iacocca, M. ;
Imielinski, M. ;
Kalloger, S. ;
Karlan, B. Y. ;
Levine, D. A. ;
Mills, G. B. ;
Morrison, C. ;
Mutch, D. ;
Olvera, N. ;
Orsulic, S. ;
Park, K. ;
Petrelli, N. ;
Rabeno, B. ;
Rader, J. S. ;
Sikic, B. I. ;
Smith-McCune, K. ;
Sood, A. K. ;
Bowtell, D. ;
Penny, R. ;
Testa, J. R. ;
Chang, K. ;
Dinh, H. H. ;
Drummond, J. A. ;
Fowler, G. ;
Gunaratne, P. ;
Hawes, A. C. ;
Kovar, C. L. ;
Lewis, L. R. ;
Morgan, M. B. ;
Newsham, I. F. ;
Santibanez, J. ;
Reid, J. G. ;
Trevino, L. R. ;
Wu, Y. -Q. ;
Wang, M. .
NATURE, 2011, 474 (7353) :609-615
[6]   PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy [J].
Bian, X. ;
Gao, J. ;
Luo, F. ;
Rui, C. ;
Zheng, T. ;
Wang, D. ;
Wang, Y. ;
Roberts, T. M. ;
Liu, P. ;
Zhao, J. J. ;
Cheng, H. .
ONCOGENE, 2018, 37 (03) :341-351
[7]   The genesis and evolution of high-grade serous ovarian cancer [J].
Bowtell, David D. L. .
NATURE REVIEWS CANCER, 2010, 10 (11) :803-808
[8]   Integrated genomic and molecular characterization of cervical cancer [J].
Burk, Robert D. ;
Chen, Zigui ;
Saller, Charles ;
Tarvin, Katherine ;
Carvalho, Andre L. ;
Scapulatempo-Neto, Cristovam ;
Silveira, Henrique C. ;
Fregnani, Jose H. ;
Creighton, Chad J. ;
Anderson, Matthew L. ;
Castro, Patricia ;
Wang, Sophia S. ;
Yau, Christina ;
Benz, Christopher ;
Robertson, A. Gordon ;
Mungall, Karen ;
Lim, Lynette ;
Bowlby, Reanne ;
Sadeghi, Sara ;
Brooks, Denise ;
Sipahimalani, Payal ;
Mar, Richard ;
Ally, Adrian ;
Clarke, Amanda ;
Mungall, Andrew J. ;
Tam, Angela ;
Lee, Darlene ;
Chuah, Eric ;
Schein, Jacqueline E. ;
Tse, Kane ;
Kasaian, Katayoon ;
Ma, Yussanne ;
Marra, Marco A. ;
Mayo, Michael ;
Balasundaram, Miruna ;
Thiessen, Nina ;
Dhalla, Noreen ;
Carlsen, Rebecca ;
Moore, Richard A. ;
Holt, Robert A. ;
Jones, Steven J. M. ;
Wong, Tina ;
Pantazi, Angeliki ;
Parfenov, Michael ;
Kucherlapati, Raju ;
Hadjipanayis, Angela ;
Seidman, Jonathan ;
Kucherlapati, Melanie ;
Ren, Xiaojia ;
Xu, Andrew W. .
NATURE, 2017, 543 (7645) :378-+
[9]   Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer [J].
Chiappa, M. ;
Guffanti, F. ;
Bertoni, F. ;
Colombo, I. ;
Damia, G. .
DRUG RESISTANCE UPDATES, 2021, 55
[10]   Oxidative stress and dietary phytochemicals: Role in cancer chemoprevention and treatment [J].
Chikara, Shireen ;
Nagaprashantha, Lokesh Dalasanur ;
Singhal, Jyotsana ;
Horne, David ;
Awasthi, Sanjay ;
Singhal, Sharad S. .
CANCER LETTERS, 2018, 413 :122-134